Pfizer Inc. (PFE), Eli Lilly & Co. (LLY) & Other Names To Know: A Full Breakdown
Investing in biotech companies can be intimidating, especially for investors without a science background. But there's hope.
Posts Tagged ‘NYSE:NVS’
Who’s Suing Novartis AG (ADR) (NVS), And Why?
Would you hold a pharmaceutical product presentation in Hooters? That's just one of many alleged instances that the U.S.
Pfizer Inc. (PFE), Novartis AG (ADR) (NVS), GlaxoSmithKline plc (ADR) (GSK) & Big Pharma’s Kickback Conundrum
Big pharma is a controversial industry. Along with tobacco companies, they are some of the most vilified businesses in the world.
Intel Corporation (INTC), Vodafone Group Plc (ADR) (VOD), and Novartis AG (ADR) (NVS): Three Misunderstood Large Cap Value Finds
Perkins Large Cap Value Fund (JNPLX) looks for temporarily misunderstood companies.
Biogen Idec Inc. (BIIB) Bounces Higher
If you thought that the great run so far in 2013 was over for Biogen Idec Inc. (NASDAQ:BIIB), think again.
Novartis AG (ADR) (NVS), Sanofi SA (ADR) (SNY), Regeneron Pharmaceuticals Inc (REGN): Three Potential Game Changers for America’s No. 1 Killer
Heart disease kills nearly 600,000 Americans every year, making it the nation's No. 1 cause of death, according to the Centers for Disease Control and Prevention.
Sanofi SA (ADR) (SNY), Johnson & Johnson (JNJ), and Investing in Potential Blockbusters
A popular drug that crosses a benchmark sale of $1 billion for the manufacturer is called a blockbuster drug.
Pfizer Inc. (PFE) & More…a ‘Breakthrough’ May Be on the Way for Breast Cancer Patients
The process of developing a drug from start to finish is incredibly arduous, usually involves around $1 billion in costs, and can take upwards of a decade to complete.
ACADIA Pharmaceuticals Inc. (ACAD), Pfizer Inc. (PFE): This Stock Is Fine, So What Just Happened to Mine?
While the Dow Jones Industrial Average (INDEXDJX:.DJI) continues to climb to new heights on little more than a central bank-induced asset levitation scheme and closing the day...
Do Hedge Funds and Insiders Love Johnson & Johnson (JNJ)?
Johnson & Johnson (NYSE:JNJ) was in 67 hedge funds' portfolio at the end of December. JNJ has experienced a decrease in hedge fund interest in recent months.
Abbott Laboratories (ABT): This Company & Ache Labs: A Perfect Match?
Abbott Laboratories (NYSE:ABT) has begun its new future swimmingly.
Pfizer Inc. (PFE): Could Novartis AG (ADR) (NVS) Decision Bring Pharma Sector Rotation?
Over the last year the biggest drug makers, like Pfizer Inc.
Biogen Idec Inc. (BIIB), Sanofi SA (ADR) (SNY), Elan Corporation, plc (ADR) (ELN): The Greatest Thing Since Sliced Bread Has Arrived for MS Patients
Last November, I examined five experimental drugs that appeared as if they had all of the tools necessary to become life-changing blockbusters from a financial and quality of ...
Do Hedge Funds and Insiders Love Novartis AG (ADR) (NYSE:NVS)?
At the moment, there are tons of gauges market participants can use to track the equity markets. A duo of the best are hedge fund and insider trading sentiment.
Pfizer Inc. (PFE), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Decision Looms on New Multiple Sclerosis Drug
Will good news from Europe echo on this side of the Atlantic within the next few days? Biogen Idec Inc. (NASDAQ:BIIB) is certainly hoping so.
AstraZeneca plc (ADR) (AZN), Sanofi SA (ADR) (SNY), GlaxoSmithKline plc (ADR) (GSK): Is It Worth Getting a Flu Shot? The Answer May Surprise You…
Every year, it appears that flu season starts earlier and earlier, and somehow, every year, the virus mutates into its "most virulent form ever." Sometimes it's a wonder we even...
GlaxoSmithKline plc (ADR) (GSK), Pfizer Inc. (PFE): Is Novartis AG (ADR) (NVS) a Cash King?
In this series, we'll highlight four companies in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting...
Pfizer Inc. (PFE), Celgene Corporation (CELG): Tackling Cancer: Lung Cancer’s Biggest Current and Upcoming Players
As I noted three weeks ago, cancer statistics are both staggering and disappointing.
Microsoft Corporation (MSFT), Intel Corporation (INTC), GlaxoSmithKline plc (ADR) (GSK): 8 Projects Bringing Synthetic Biology to Your Doorstep
Bacteria have been Public Enemy No. 1 for most of our species' time on Earth.
Insmed Incorporated (INSM) Earnings: An Early Look
Earnings season is winding down, with most companies already having reported their quarterly results.
Does Novartis AG (ADR) (NVS)’s Dividend Have Room to Soar?
With interest rates still sitting near record lows, looking for current income have been forced to move away from fixed-income positions and into stocks to find yield.
Can Myriad Genetics, Inc. (MYGN) Survive the Supreme Court?
The market has been less than thrilled about an upcoming Supreme Court decision on the legality of the best-selling analytical test of Myriad Genetics, Inc. (NASDAQ:MYGN) .
Will Novartis (NVS) Help You Retire Rich?
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
The Fight Over This Biotech’s Cash: Elan Corporation, plc (ADR) (ELN)
Elan Corporation, plc (ADR) (NYSE:ELN) was nice enough to give us a little more detail on what it plans to do with the $3.25 million that the biotech stands to get from Biogen...
Dendreon Corporation (DNDN) Earnings: An Early Look
Earnings season is now starting to wind down, with most companies already having reported their quarterly results.
Can JAK Inhibitors Challenge Biologics?: Johnson & Johnson (JNJ) and More
When the word "biotechnology" gets thrown around in the pharmaceutical industry, it often implies the biomanufacturing of biologic drugs, such as therapeutic proteins.
Will Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Rule This Multibillion-Dollar Market?
Back in 2011, generic drug giant Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) dominated the MS field, riding the coattails of its Copaxone medication to success.
A Win-Win Multiple Sclerosis Deal? – Biogen Idec Inc. (BIIB), Elan Corporation, plc (ELN)
Biogen Idec Inc. (NASDAQ:BIIB) is buying the full rights to multiple sclerosis drug Tysabri from Elan Corporation, plc (ADR) (NYSE:ELN) for $3.25 billion.
Buy, Sell, or Hold: Astex Pharmaceuticals, Inc. (ASTX)
When considering any stock for your portfolio, don't be swayed by just the positives. Examine its pros and cons and decide whether its possible upside outweighs its risks.
3 Things to Watch at Momenta Pharmaceuticals, Inc. (MNTA)
Despite its name, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has been losing steam since the end of 2011 with revenue falling 97% in the last nine months.
